Pilot study shows cfDNA methylation of DUSP22 relates to severity in rheumatoid arthritis, suggesting a new biomarker.
Our pilot study is the first to evaluate cfDNA methylation association to RA clinical characteristics. These exploratory findings suggest that DUSP22 cfDNA methylation may represent a promising non-invasive biomarker in rheumatoid arthritis, a hypothesis that warrants validation in larger and ethnically diverse populations.
No takes yet. Share an insight, caveat, or question.
Delgado-Cruzata et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: